Safety and Pharmacokinetics of the Novel BACE Inhibitor MK-8931 in Healthy Subjects Following Single Dose Administration

Trial Profile

Safety and Pharmacokinetics of the Novel BACE Inhibitor MK-8931 in Healthy Subjects Following Single Dose Administration

Completed
Phase of Trial: Phase I/II

Latest Information Update: 07 Aug 2012

At a glance

  • Drugs Verubecestat (Primary)
  • Indications Alzheimer's disease
  • Focus Adverse reactions
  • Most Recent Events

    • 07 Aug 2012 New trial record
    • 19 Jul 2012 Results from a pooled analysis presented at the 2012 International Conference on Alzheimer's Disease.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top